Last Updated : November 29, 2023
Details
FilesGeneric Name:
zanubrutinib
Project Status:
Complete
Therapeutic Area:
Chronic lymphocytic leukemia /small lymphocytic lymphoma.
Manufacturer:
BeiGene Canada ULC
Call for patient/clinician input open:
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0310-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of
adult patients with chronic lymphocytic leukemia (CLL).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of
adult patients with chronic lymphocytic leukemia (CLL).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 15-Dec-22 |
|---|---|
| Call for patient/clinician input closed | 13-Feb-23 |
| Clarification: - Patient input submission received from Lymphoma Canada. | |
| Submission received | 20-Jan-23 |
| Submission accepted | 06-Feb-23 |
| Review initiated | 07-Feb-23 |
| Draft CADTH review report(s) provided to sponsor for comment | 25-Apr-23 |
| Deadline for sponsors comments | 05-May-23 |
| CADTH review report(s) and responses to comments provided to sponsor | 29-Jun-23 |
| Expert committee meeting (initial) | 12-Jul-23 |
| Draft recommendation issued to sponsor | 24-Jul-23 |
| Draft recommendation posted for stakeholder feedback | 03-Aug-23 |
| End of feedback period | 18-Aug-23 |
| Final recommendation issued to sponsor and drug plans | 01-Sep-23 |
| Final recommendation posted | 20-Sep-23 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | 18-Sep-23 |
| CADTH review report(s) posted | 29-Nov-23 |
Files
Last Updated : November 29, 2023